Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on June 2, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

2-PAM Autoinjectors Project Bioshield

Closed
75A50126R00002Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The contract involves BARDA seeking a contractor for the late-stage clinical development and regulatory approval of 2-PAM autoinjectors, which are designed as a drug/device combination product to treat organophosphate poisoning, including exposure to nerve agents, applicable for both adult and pediatric populations. Additionally, the contract includes the procurement of these autoinjectors for the Strategic National Stockpile (SNS) and the CHEMPACK program. This presolicitation notice outlines the government's interest in advancing this important medical countermeasure to address chemical threats. The solicitation, titled "2-PAM Autoinjectors Project Bioshield," was posted on June 2, 2026, with a response deadline on June 16, 2026. It is managed by the Department of Health and Human Services under the BARDA office located in Washington, DC. The contract falls under the NAICS code 541714, indicating a focus on research and development in biotechnology. The notice does not specify any set-aside provisions. Points of contact include Erin Greninger as the primary contracting officer and Greg Smith as the secondary contact. The place of performance is in Washington, DC, reflecting the administrative and oversight location for this government-funded effort.

General Info

BARDA seeks contractor for 2-PAM autoinjector development, approval, and procurement for chemical threat response.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Washington, DC, 20024, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

Presolicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
Contacts2 people available
OfficeWASHINGTON, DC, 20515, USA
Organization / Agency
Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
Office AddressWASHINGTON, DC, 20515, USA
Contacts
Erin Greninger Contracting Officer

Full Description

Show more

This is a presoliciation notice for the following:


BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.